Home » cGMP Compliance is Pharma’s Top Manufacturing Goal, Preliminary Survey Results Suggest
cGMP Compliance is Pharma’s Top Manufacturing Goal, Preliminary Survey Results Suggest
By Agnes Shanley
So far, 75 people have responded to our latest mini-survey on manufacturing excellence and goals for the year. Of these respondents, 45 answered every question in the brief survey. The results, while not statistically important, still suggest some trends.
What follows is a quick summary of interim results. The survey will remain open, and we invite you to take three minutes to complete it (we are also offering a nominal incentive. To take the survey, or more information, visit http://www.surveygizmo.com/s3/1040818/Pharmaceutical-Manufacturing-Operational-Excellence-Survey-2012)
When asked whether manufacturing operations were becoming more complex. 22% of respondents said complexity had increased significantly. Nearly 48% said they had become “somewhat more complex.” Nearly 27% said they had remained unchanged, with around 3% saying they had become less complex.
When asked to rank their priorities in order of importance, the following weighted priority list took shape:
Improving GMP compliance
Improving product quality
Reducing cycle time
Reducing setup and changeover time
Top pharmaceutical product quality goals were as follows, ranked in order of importance:
Eliminating variability in final product
Improving raw material quality
Improving supplier oversight
Reducing scrap time
When asked whether their organizations had methods in place to assess the cost of poor quality and noncompliance, over 64% said they did, while the remainder did not.
Respondents ranked their most strategically important Op Ex methods as follows:
Statistical Process Control
Process Capability Analysis
Several years ago, manufacturing was described as a "stepchild" function at many companies, and a few survey questions probed this area. When asked how important manufacturing was to their organizations’ overall business strategies, over 62% said it was very important, with 24% responding “important,” 11% “moderately important,” and the remainder not important.
Survey responses also suggest that manufacturing is working more closely with both development and quality control functions, suggesting that more pharmaceutical manufacturing facilities, and companies, may be moving away from traditional silos and adopting a more crossfunctional approach to daily operations.
Nearly 76% of respondents said manufacturing was working “much more closely” or “more closely” with development. 84% said that manufacturing was working more closely or much more closely with QC functions.
In addition 78% said that top managers at their organizations came from the manufacturing function.
Aragon Purchased For $650M+From USA Today
Johnson & Johnson has agreed to buy Aragon Pharmaceuticals for at least $650 million in cash.
ASME BPE Certifies MaxPure Stainless-Steel Fittings
TEK Stainless Piping Products announces certification of MaxPure, EGMO’S stainless-steel fitting product line for bioprocessing industry
Supreme Court Rules Against 'pay-to-delay'From Economic Times
Big pharma companies lose in Supreme Court's 'pay-to-delay' decision.
BioScrip Acquires CarePoint for $223 MillionFrom Bloomberg Businessweek
BioScrip Inc. plans to expand its drug infusion business with a new acquisition of CarePoint for $223 million.
Endress+Hauser Offers Online Thermowell Sizing Calculator
Free, online thermowell calculation tool compliant with new ASME PTC 19.3 TW-2010 standards simplifies engineer work
Supreme Court DNA Ruling Could Hurt Biotech IndustryFrom The Denver Post Politics
Critics said the ruling would discourage other companies and financial backers from investing in more genetic sequencing research
Supreme Court Says No to Patenting Human GenesFrom The Scientist
The Court unanimously ruled that isolated sequences of human DNA are not eligible for patent protection, but artificial sequences can be patented
All-new Pharma EXPO Debuts in November 2014
Co-located with PACK-EXPO International, ISPE Pharma EXPO will be held in Chicago
Canadian Health Authority Accepts Use of Roche's Rapid Mycoplasma Detection TestFrom Roche
Roche’s Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian Authorities for Release Testing of Biopharmaceutical Roche Product
Over 200 Cardiovascular Disease Drugs in DevelopmentFrom Drug Store News
According a recent report, 215 drugs are now under development for heart disease and stroke.
- All news »